Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.

@article{Yeung2011ClinicalEO,
  title={Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial.},
  author={Alan Yeung and Martin B. Leon and Ash Jain and Thaddeus R Tolleson and Douglas J Spriggs and Brent T Mc Laurin and Jeffrey J. Popma and Peter J. Fitzgerald and Donald E. Cutlip and Joseph M. Massaro and Laura Mauri},
  journal={Journal of the American College of Cardiology},
  year={2011},
  volume={57 17},
  pages={1778-83}
}
OBJECTIVES The RESOLUTE US (R-US) trial is a prospective, observational study designed to evaluate the clinical effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) in a U.S. population. BACKGROUND The R-ZES releases zotarolimus over a 6-month period in order to achieve optimal clinical effectiveness and safety. METHODS The R-US trial recruited patients with de novo native coronary lesions suitable for 1- or 2-vessel treatment with stents from 2.25 to 4.0 mm in diameter. In the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

TCT-282: one year outcomes of patients with Resolute zotarolimus-eluting stent: results of the RESOLUTE International Registry (abstr)

  • P Widimsky, JA Belardi, F-J. Neumann
  • J Am Coll Cardiol
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…